Relevant reading: rheumatic irAEs
Key reviews on rheumatic irAEs
​
Rheumatic immune-related adverse events from cancer immunotherapy.
https://doi.org/10.1038/s41584-018-0074-9
​
Australian rheumatic irAE-relevant data
​
Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression.
https://doi.org/10.1371/journal.pone.0192704
​
Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.
https://doi.org/10.1016/j.ejca.2018.09.027
​
Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy.
https://doi.org/10.1111/1756-185X.13444
​
Comments from Aus-REISAMIC members on rheumatic irAEs
​
Checkpoint inhibitors and arthritis.
https://doi.org/10.1136/annrheumdis-2018-213415
​
Letter to the editor: Comments on ‘A case of pembrolizumab-induced autoimmune haemolytic anaemia with polymyalgia rheumatica’.